Sankala Group’s Royalty Pharma RPRX Stock Holding History

Sankala Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.3K	Hold	197	–	–	0.01%	391
2025 Q4	$9.1K	Buy	+197	New	+$7.51K	0.01%	399

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sankala Group's RPRX Position: Q1 2026 in Review

Sankala Group held its Royalty Pharma (RPRX) position steady in Q1 2026 at 197 shares worth $9.3K. The position accounts for 0.01% of the portfolio, ranked #391.

Sankala Group first reported a position in RPRX in Q4 2025 and has held it in 2 quarters since. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Sankala Group held 197 shares of Royalty Pharma worth $9.3K as of Q1 2026.
Sankala Group left its Royalty Pharma share count unchanged in Q1 2026.
Royalty Pharma made up 0.01% of Sankala Group's portfolio in Q1 2026, its #391 holding.
Sankala Group first reported a position in Royalty Pharma in Q4 2025 and has held it in 2 quarters since.
590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.